Comparative evaluation of local drug delivery using tetracycline fibers and antimicrobial photodynamic therapy in Stage II Grade B periodontitis: A clinico-microbiological study Authors: Priya Toshniwal, Jayashree A. Mudda, Shrikar Desai, R Aniketh, Sahana Jain Published: 2024 ABSTRACT Background:Periodontal therapy aims to eliminate the periopathogens involved in disease progression to restore the lost form and function of the tooth-supporting structures. To overcome the drawbacks of conventional treatment, several adjunctive treatment modalities have been successfully used to treat moderate-to-severe periodontal diseases. The present study aims to comparatively evaluate the efficacy of locally delivered tetracycline fibers and antimicrobial photodynamic therapy (PDT) as an adjunct to nonsurgical periodontal treatment, focusing on the possibility of improving the clinical parameters and reducing the microbial load postoperatively.Materials and Methods:Twenty-two patients with Stage II Grade B periodontitis were divided into two groups: Group A: scaling and root planing (SRP) + locally delivered tetracycline fibers and Group B: SRP + antimicrobial PDT using indocyanine green as photosensitizer. The following clinical parameters were assessed at baseline, 3 months, and 6 months: Gingival index, modified sulcular bleeding index, clinical attachment level, and probing pocket depth. Subgingival plaque samples were obtained for microbial analysis of Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, and Prevotella intermedia at the following periods.Results:There was significant improvement in clinical and microbiological parameters in both the groups at 3 months and 6 months postoperatively. Microbial recolonization was noted in both the groups, albeit without reaching statistical significance with respect to P. gingivalis and A. actinomycetemcomitans at 6 months postoperatively.Conclusion:From the results obtained, it can be concluded that both local drug delivery and antimicrobial PDT can be used as an effective adjunctive treatment to SRP. However, supportive periodontal care is required to avoid microbial recolonization. INTRODUCTION More than 300 species of bacteria recognized in the oral cavity are responsible for an ill-defined series of microbial infections of the periodontium resulting in an inflammatory disease known as periodontitis.[1] Supragingival plaque predominantly consists of Gram-positive coccoid cells, while subgingival plaque is characterized by a flora dominated by Gram-negative anaerobic organisms.[2] Entire host tissue and intercellular matrix molecules are degraded by the enzymes produced by periodontal microorganisms.[23] There is an increase in the level of proinflammatory mediators such as interleukin-1 β (IL-1 β), IL-6, tumor necrosis factor-α, and increase in lipopolysaccharides, all of which are induced by periodontal bacteria.[45] This in turn results in the activation of osteoclasts.[6] Hence, the removal of plaque-loaded bacteria is an important step in periodontal therapy. Scaling and root planing (SRP) is the gold standard for reducing biofilm in the nonsurgical management of periodontal disease. However, SRP is inefficient in eliminating periodontal pathogens found in deep periodontal pockets. Because of this, there is microbial recolonization from the persisting subgingival plaque and other oral reservoirs. This recolonization of microbes can be prevented with routine periodontal maintenance, including coadjuvants such as antibiotics and photodynamic therapy (PDT) with mechanical debridement. Healing of attachment apparatus and alteration of subgingival flora is possible with a subgingivally placed controlled delivery system that is capable of maintaining effective intrapocket levels of antibacterial agents for a sufficient duration of time.[78] One such agent is tetracycline which can achieve gingival fluid levels by 2–4 times more than that of blood levels.[910] It favors reattachment or regeneration by increasing the attachment of fibroblasts, inhibits the activity of collagenase, and also helps in root surface conditioning.[11] Over the years, antimicrobial PDT (aPDT) has garnered significant attention as a novel noninvasive approach for infection control in oral diseases. This technique utilizes low-level laser light combined with a photosensitizer to achieve its effects. aPDT offers several benefits, including noninvasiveness, decrease in the risk of bacteremia, reduction of bacterial resistance, reduced need for flap surgery, and elimination of local anesthetics thereby making it a compelling option.[12] One of the prime advantages of aPDT as a therapy is its dual selectivity. The selective accumulation of photosensitizer in the diseased tissue followed by delivery of light in a spatially focused and confined manner will largely prevent collateral damage to the adjacent, healthy tissue.[13] Historically, indocyanine green (ICG) which was approved by the Food and Drug Administration in 1954 was initially used in the diagnosis of hepatic function and cardiology.[14] Recently, ICG has gained special attention in the field of dentistry because of its antibacterial activity, low toxicity, absorption peak being close to the emission of a maximum of dental diode lasers (wavelength which is within visible red light and near-infrared), and rapid elimination of ICG.[15] ICG’s lack of dependence on O2 enhances its effectiveness in anaerobic subgingival areas compared to other photosensitizers, making it a valuable treatment for periodontitis.[16] Hence, the present study aims to comparatively evaluate the efficacy of locally delivered tetracycline and aPDT using a diode laser, as an adjunct to nonsurgical periodontal treatment in patients with Stage II Grade B periodontitis. MATERIALS AND METHODS The study design was a randomized controlled trial with a parallel group design. The sample size was calculated to be 22 patients (10 men and 12 women) with the age group of 30–60 years (mean 45 ± 2) who are diagnosed with Stage II Grade B periodontitis as given in the consort chart [Figure 1]. These subjects were selected from the periodontics outpatient clinic. Ethical approval was obtained from the institutional ethics committee. Written consent was taken from all recruited patients. Consort chart showing random allocation of subjects to Group A (scaling and root planing [SRP] + local drug delivery) and Group B (SRP + antimicrobial photodynamic therapy) The inclusion criteria were as follows: Patients of 30–60 years of ageSystemically healthy patientsPatients diagnosed with Stage II Grade B periodontitis with no grade modifiers presentProbing pocket depth (PPD) of ≥5 mm. Patients of 30–60 years of age Patients of 30–60 years of age Systemically healthy patients Systemically healthy patients Patients diagnosed with Stage II Grade B periodontitis with no grade modifiers present Patients diagnosed with Stage II Grade B periodontitis with no grade modifiers present Probing pocket depth (PPD) of ≥5 mm. Probing pocket depth (PPD) of ≥5 mm. The exclusion criteria were as follows: History of underlying systemic disease necessitating long-term medication usePregnant or lactating womenPatients who had undergone any nonsurgical periodontal therapy in the past 6 monthsPatients with a history of allergy to tetracycline or ICGChronic smokers, alcoholics, or patients with any adverse habits were excluded from the study. History of underlying systemic disease necessitating long-term medication use History of underlying systemic disease necessitating long-term medication use Pregnant or lactating women Pregnant or lactating women Patients who had undergone any nonsurgical periodontal therapy in the past 6 months Patients who had undergone any nonsurgical periodontal therapy in the past 6 months Patients with a history of allergy to tetracycline or ICG Patients with a history of allergy to tetracycline or ICG Chronic smokers, alcoholics, or patients with any adverse habits were excluded from the study. Chronic smokers, alcoholics, or patients with any adverse habits were excluded from the study. All study subjects underwent an oral examination and the following clinical parameters were recorded: Gingival index (GI) (Loe and Sillness, 1963)Modified sulcular bleeding index (mSBI) (Mombelli et al., 1987)PPDClinical attachment level (CAL). Gingival index (GI) (Loe and Sillness, 1963) Gingival index (GI) (Loe and Sillness, 1963) Modified sulcular bleeding index (mSBI) (Mombelli et al., 1987) Modified sulcular bleeding index (mSBI) (Mombelli et al., 1987) PPD PPD Clinical attachment level (CAL). Clinical attachment level (CAL). The microbiological evaluation was done in relation to Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, and Prevotella intermedia. The patients were allocated into two groups of 11 individuals using the computerized random block allocation method. Group A: (n = 11): SRP + local drug delivery (LDD)Group B: (n = 11): SRP + aPDT using ICG photosensitizer. Group A: (n = 11): SRP + local drug delivery (LDD) Group A: (n = 11): SRP + local drug delivery (LDD) Group B: (n = 11): SRP + aPDT using ICG photosensitizer. Group B: (n = 11): SRP + aPDT using ICG photosensitizer. The procedure comprised of SRP that was performed in all patients on 1st day, and then, patients were recalled after 1 week. In Group A, after isolating the area with cotton rolls, tetracycline fibers (Periodontal Plus AB®) were soaked in saline [Figure 2]. Short lengths of fibers (2–3 inches) were then carefully placed into the periodontal pockets using tweezers [Figure 3]. This was followed by the application of a non-eugenol periodontal dressing (Coe-Pak™) [Figure 4], which was removed after two weeks. Figure 5 shows probing pocket depth after two weeks. In Group B, the ICG photosensitizer was dissolved in 5 mL of sterile water to prepare an initial stock solution of 5 mg/mL ICG. This solution was then further diluted in saline at a ratio of 1:5 to achieve a final ICG concentration of 1 mg/mL [Figure 6] For group B, preoperative probing pocket depth was recorded before starting the procedure [Figure 7]. Intrapocket delivery of 0.5–1 ml of ICG solution was done using a blunt needle. After a 60-s delivery period, a diode laser with a 980 nm wavelength and 0.8 W power output (in continuous mode), equipped with a probe tip, was placed at the depth of the pocket and moved circumferentially around the tooth for 1 min [Figure 8]. Residual photosensitizer was then wiped thoroughly after the activation cycle was completed to prevent potential tissue irritation, minimize any adverse effects, and reduce unnecessary exposure to photosensitizer. Figure 9 shows probing pocket depth after two weeks. Tetracycline fibers (local drug delivery) Group A: Tetracycline fibers placed in the pocket COE-PAK placed Group A: Postoperative probing pocket depth after two weeks Diluted indocyanine green photosensitizer Group B: Preoperative probing pocket depth Intrapocket delivery of diluted indocyanine green photosensitizer followed by photodynamic therapy using 980 nm diode laser Group B: Postoperative probing pocket depth after 2 weeks For microbiological sample analysis, subgingival plaque sample was collected using a sterile curette from both Group A and Group B subjects and was stored in a reduced transport fluid (RTF) medium [Figure 10]. Samples were sent within 24 h to Maratha Mandal Institute of Dental Sciences and Research in Belgaum, Karnataka, for semiquantitative analysis using the polymerase chain reaction (PCR) technique. Vials containing reduced transport fluid medium RTF medium was composed of stock mineral salt solution no. 1 (75 ml), stock mineral salt solution no. 2 (75 ml), 0.1 M ethylenediaminetetraacetic acid (10 ml), 8% sodium carbonate (5 ml), 1% dithiothreitol (20 ml), resazurin 0.1% (1 ml), and distilled water (814 ml). In the microbiological laboratory, organisms from the subgingival plaque sample were analyzed semiquantitatively using the PCR technique following DNA extraction through the modified proteinase K method. The following set of PCR primers were used which are specific to respective organisms: P. gingivalis: 404 base pairAGG CAG CTT GCC ATA CTG CGACT GTT AGC AAC TAC CGA TGT.A. actinomycetemcomitans: 443 base pairGCT AAT ACC GCG TAG AGT CGGATT TCA CAC CTC ACT TAA AGG T.P. intermedia: 589 base pairAAC GGC ATT ATG TGC TTG CACCTC AAG TCC GCC AGT TCG CG. P. gingivalis: 404 base pairAGG CAG CTT GCC ATA CTG CGACT GTT AGC AAC TAC CGA TGT. P. gingivalis: 404 base pair AGG CAG CTT GCC ATA CTG CG AGG CAG CTT GCC ATA CTG CG ACT GTT AGC AAC TAC CGA TGT. ACT GTT AGC AAC TAC CGA TGT. A. actinomycetemcomitans: 443 base pairGCT AAT ACC GCG TAG AGT CGGATT TCA CAC CTC ACT TAA AGG T. A. actinomycetemcomitans: 443 base pair GCT AAT ACC GCG TAG AGT CGG GCT AAT ACC GCG TAG AGT CGG ATT TCA CAC CTC ACT TAA AGG T. ATT TCA CAC CTC ACT TAA AGG T. P. intermedia: 589 base pairAAC GGC ATT ATG TGC TTG CACCTC AAG TCC GCC AGT TCG CG. P. intermedia: 589 base pair AAC GGC ATT ATG TGC TTG CAC AAC GGC ATT ATG TGC TTG CAC CTC AAG TCC GCC AGT TCG CG. CTC AAG TCC GCC AGT TCG CG. Sample size estimation was performed using G power software, version 3.0, University of Düsseldorf, Germany.[17] The estimation, based on an independent t-test, determined that a minimum total sample size of 22 would be sufficient. This calculation was made with an alpha of 0.05, a power of 80%–90%, and an effect size of 1.11. Thus, the minimum sample size was found to be 11 patients each in two study groups. Data were entered into a Microsoft Excel spreadsheet and checked for discrepancies. Summarized data were presented using tables and graphs. The data were analyzed using SPSS version 21.0 (developed by IBM, USA). The Shapiro–Wilk test was used to check for variables that followed a normal distribution. Since the data were not normally distributed (P < 0.05), bivariate analyses were performed using nonparametric tests: the Mann–Whitney U-test for comparing two groups and the Wilcoxon rank sum test for intragroup comparison. The level of statistical significance was set at P < 0.05. RESULTS The study included patients within the age group of 30–60 years, all of whom fulfilled the inclusion criteria by exhibiting Stage II Grade B periodontitis. All participants completed the study. The examiner calibrated and recorded the clinical and microbiological parameters at three time points: baseline (T0), 3 months (T1), and 6 months (T2). On intergroup comparison of microbial colony count (colony forming units), no significant difference was observed at T0, T1, and T2 as P > 0.05 [Table 1 and Graph 1]. On intragroup comparison, microbial colony count was increased in both the groups from baseline to 6 months (T0–T2), although the data were statistically nonsignificant. In Group A subjects, the colony count of P. gingivalis and A. actinomycetemcomitans was increased, whereas only P. intermedia count was reduced from T0 to T2 [Table 2 and Graph 2a]. In Group B subjects, both P. gingivalis and P. intermedia count was reduced significantly whereas only A. actinomycetemcomitans count was slightly increased from T0 to T2 [Table 2 and Graph 2b]. On intergroup comparison of clinical parameters (GI, mSBI, PPD, and CAL), no significant difference was observed at T0, T1, and T2 [Tables 3, 4 and Graphs 3 and 4]. On intragroup comparisons, there was a statistically significant reduction in all clinical parameters (GI, mSBI, PPD, and CAL) from T0 to T2 in both Group A [Tables 5, 6 and Graphs 5a and 6a] and Group B subjects [Tables 5, 6 and Graphs 5b and 6b]. Table 1Intergroup comparison of microbial colony counts (colony forming units)Mean±SD P P. gingivalis T0 Group A91,406,312.50±159,054,004.3320.146 Group B4,573,912.50±11,045,587.741 T1 Group A17,332.50±29,569.1990.467 Group B3573.33±1161.737 T2 Group A2933.33±1651.0100.835 Group B2565.00±2015.254 A. actinomycetemcomitans T0 Group A219,363.33±216,223.2360.058 Group B22,096,571.43±25,205,335.638 T1 Group A8333.33±1154.7010.133 Group B6000.00±1414.214 T2 Group A2800.00±2262.7420.554 Group B1625.00±671.751 P. intermedia T0 Group A1,534,642.86±2,313,657.9390.796 Group B1,187,005.00±2,421,943.339 T1 Group A1950.00±526.7830.789 Group B1750.00±1060.660 T2 Group A1116.67±104.0830.239 Group B2625.00±1944.544SD – Standard deviation; P. gingivalis – Porphyromonas gingivalis; P. intermedia – Prevotella intermedia; A. actinomycetemcomitans – Aggregatibacter actinomycetemcomitans; P – Probability value Intergroup comparison of microbial colony counts (colony forming units) SD – Standard deviation; P. gingivalis – Porphyromonas gingivalis; P. intermedia – Prevotella intermedia; A. actinomycetemcomitans – Aggregatibacter actinomycetemcomitans; P – Probability value When Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Prevotella intermedia colony count were compared among Group A and Group B subjects at T0, T1, and T2, no significant differences were observed when assessed using Mann–Whitney U-test as P > 0.05 Table 2Intragroup comparison of microbial colony counts in Group A subjects (CFU’s)Mean±SD P P. gingivalis T0–T193,669,667.5±165,382,288.10.340 T0–T2113,820,733.3±196,740,418.00.422 A. actinomycetemcomitans T0–T1191,393.3±283,711.00.363 T0–T2327,200.0±139,158.60.186 P. intermedia T0–T13,104,716.6±3,071,377.10.222 T0–T2554,550.0±91,420.80.009* Intragroup comparison of microbial colony counts in Group B subjects (CFUs) P. gingivalis T0–T111,822,426.667±17,340,648.5120.359 T0–T228,435.000±7884.2410.123 A. actinomycetemcomitans T0–T15,099,000.000±786,302.7410.069 T0–T248,198,375.000±17,112,655.8560.157 P. intermedia T0–T13,406,250.000±3,806,002.2500.426 T0–T2146,375.000±127,809.5510.352*Prevotella intermedia count significantly decreased in Group A subjects from T0-T2: P<0.05. SD – Standard deviation; P. gingivalis – Porphyromonas gingivalis; P. intermedia – Prevotella intermedia; A. actinomycetemcomitans – Aggregatibacter actinomycetemcomitans; CFU – Colony forming units; P – Probability value Intragroup comparison of microbial colony counts in Group A subjects (CFU’s) *Prevotella intermedia count significantly decreased in Group A subjects from T0-T2: P<0.05. SD – Standard deviation; P. gingivalis – Porphyromonas gingivalis; P. intermedia – Prevotella intermedia; A. actinomycetemcomitans – Aggregatibacter actinomycetemcomitans; CFU – Colony forming units; P – Probability value (a) No significant difference was seen in the Porphyromonas gingivalis count and Aggregatibacter actinomycetemcomitans count from T0 to T1 and T0 to T2 whereas Prevotella intermedia count was significantly decreased in Group A subjects from T0 to T2 as P < 0.05, (b) In Group B subjects, both Porphyromonas gingivalis and Prevotella intermedia count was reduced significantly whereas Aggregatibacter actinomycetemcomitans count was increased from TO-T2, although statistically non significant as P>0.05 Table 3Intergroup comparison of gingival index and modified sulcular bleeding indexGroupMean±SD P GI T0Group A2.4000±0.624500.959Group B2.3864±0.60419 T1Group A1.3545±0.448030.121Group B1.0300±0.49000 T2Group A0.7836±0.322250.220Group B0.5982±0.36364SBI T0Group A2.636±0.50451.00Group B2.636±0.5045 T1Group A1.000±0.63250.422Group B0.727±0.9045 T2Group A0.455±0.52220.687Group B0.545±0.5222SBI – Sulcular bleeding index; GI – Gingival index; SD – Standard deviation; P – Probability value Intergroup comparison of gingival index and modified sulcular bleeding index SBI – Sulcular bleeding index; GI – Gingival index; SD – Standard deviation; P – Probability value No significant difference was seen in mean gingival index and modified sulcular bleeding index when intergroup comparison was made at T0, T1, and T2 time intervals as P > 0.05 Table 4Intergroup comparison of mean probing pocket depth (mm) and clinical attachment level (mm)GroupMean±SD P PPD T0Group A5.182±0.40450.631Group B5.273±0.4671 T1Group A2.909±0.70060.036Group B3.636±0.8090 T2Group A2.364±0.50450.027Group B2.000±0.0000CAL T0Group A6.182±0.98160.546Group B6.000±0.0000 T1Group A3.909±1.37510.829Group B4.000±0.0000 T2Group A3.364±0.8090<0.001Group B2.000±0.0000PPD – Probing pocket depth; CAL – Clinical attachment level; SD – Standard deviation; P – Probability value. Significant reductions were seen in the mean gingival index and modified sulcular bleeding index of Group A subjects from T0–T1 and T0–T2 as P<0.05 Intergroup comparison of mean probing pocket depth (mm) and clinical attachment level (mm) PPD – Probing pocket depth; CAL – Clinical attachment level; SD – Standard deviation; P – Probability value. Significant reductions were seen in the mean gingival index and modified sulcular bleeding index of Group A subjects from T0–T1 and T0–T2 as P<0.05 No significant differences were observed in probing pocket depth and clinical attachment level of two study groups at T0 and T1 but at T2, clinical attachment level of Group A subjects was found to be significantly more as P < 0.05 Table 5Intragroup comparison of GI and mSBI in Group A subjectsMean±SD P GI T0–T11.04545±0.469820.000* T0–T21.61636±0.566080.000*SBI T0–T11.6364±0.80900.000* T0–T22.1818±0.60300.000* Intragroup comparison of GI and mSBI in Group B subjects GI T0–T11.35636±0.414060.000* T0–T21.78818±0.686390.000*SBI T0–T11.9091±0.70060.000* T0–T22.0909±0.83120.000**Significant reductions seen in mean GI and mSBI of Group A subjects from T0-T1 and T0-T2: P<0.05. GI – Gingival index; SBI – Sulcular bleeding index; mSBI – Modified SBI; SD – Standard deviation; P – Probability value Intragroup comparison of GI and mSBI in Group A subjects *Significant reductions seen in mean GI and mSBI of Group A subjects from T0-T1 and T0-T2: P<0.05. GI – Gingival index; SBI – Sulcular bleeding index; mSBI – Modified SBI; SD – Standard deviation; P – Probability value (a) Significant reductions were seen in the mean gingival index and Modified sulcular bleeding index of Group A subjects from T0 to T1 and T0 to T2 as P < 0.05, (b) Significant reductions were seen in mean gingival index and Modified sulcular bleeding index of Group B subjects from T0 to T1 and T0 to T2 as P < 0.05 Table 6Intragroup comparison of PPD (mm) and clinical attachment level (mm) in Group A subjectsMean±SD P PPD T0–T12.2727±0.78620.000* T0–T22.8182±0.40450.000*CAL T0–T12.2727±0.78620.000* T0–T22.8182±0.40450.000* Intragroup comparison of PPD (mm) in Group B subjects PPD T0–T11.6364±0.92440.000* T0–T23.2727±0.46710.000**Significant reductions seen in mean PPD and CAL of Group A subjects from T0-T1 and T0-T2: P<0.05. PPD – Probing pocket depth; CAL – Clinical attachment level; SD – Standard deviation; P – Probability value Intragroup comparison of PPD (mm) and clinical attachment level (mm) in Group A subjects *Significant reductions seen in mean PPD and CAL of Group A subjects from T0-T1 and T0-T2: P<0.05. PPD – Probing pocket depth; CAL – Clinical attachment level; SD – Standard deviation; P – Probability value (a) Significant reductions were seen in mean probing pocket depth and clinical attachment level of Group A subjects from T0 to T1 and T0 to T2 as P < 0.05, (b) Significant reductions were seen in mean probing pocket depth of Group B subjects from T0 to T1 and T0 to T2 as P < 0.05. There was no change in the clinical attachment level after 3 months interval hence, the correlation and time interval cannot be computed because the standard error of difference was 0 DISCUSSION The current study’s results revealed that both groups exhibited to be effective clinically and microbiologically as an adjunct to NSPT. For antimicrobial agents to be effective, the drug concentration at the site must be adequate, and there should be prolonged contact between the drug and the microorganisms. Tetracyclines are superior to other antibiotics because they uniquely retain in tooth cementum and soft tissues, achieving higher concentrations in gingival fluid than in serum.[18] Tetracycline has also been proven to inhibit collagenase activity, collagen degradation, and bone resorption, as reported by Golub et al.[19] The drug exhibits its antimicrobial effect by inhibiting protein synthesis. Periodontal Plus AB® (PPAB) is a collagen fibril-based formulation containing tetracycline hydrochloride (2 mg of tetracycline) in 25 mg of collagen fibrils. It has a dual mode of action through the active agent, tetracycline, and the vehicle, Type I collagen. PPAB releases tetracycline consistently for over 10–14 days with concentration reaching a peak on the 4th–5th day. As a synergistic effect, the biodegradation of collagen fibrils releases enzymes that facilitate the healing of periodontal tissues. On the other hand, PDT enhances the antibacterial effect of lasers with the help of a photosensitizing dye. The working principle involves the production of a highly reactive state of oxygen when the photosensitizer undergoes the transition from a low-energy ground state to a high-energy triplet state.[20] There are two pathways in which this triplet state photosensitizer can react with biomolecules; in the Type I pathway, free radicals are produced as there is an electron transfer reaction that leads to the interaction of the organic substrate molecule of the cell with the excited state of the photosensitizer. In the Type II pathway, there is oxidative damage due to the interaction of various biological substrates induced by the interaction of oxygen with triplet state photosensitizer leading to the formation of singlet oxygen which is responsible for toxic effects on the bacterial cell. This singlet oxygen produced in the Type II pathway acts at about 0.02 μm. It has very little possibility of developing photoresistant bacterial strains and has a short half-life.[2122] ICG which is a tricarboxy cyanine, exhibits 20% photodynamic effect along with hydrophilic and lipophilic properties. The main action of ICG is through the photothermal effect where there is an increase in intracellular temperature that leads to cell damage.[23] Because of these properties of ICG, there is reduced bleeding and limited destruction of pocket epithelium. While 810 nm is considered optimal for ICG, research has shown that ICG can also be effectively activated by wavelengths in the range of 700 to 980 nm.[24] The 980 nm wavelength used in the current study falls within this broader spectrum of effective wavelengths for ICG absorption. The 980 nm diode laser offers adjustable parameters, such as power output, exposure time, and irradiation mode (continuous or pulsed), which can be optimized for the desired therapeutic effect when used with ICG. In the present study, on the intergroup and intragroup comparison [Tables 3–6 and Graphs 3, 4, 5a and b, 6a and b], there was a significant reduction in all the clinical parameters (GI, SBI, PPD, and CAL) in both the groups from baseline to 6 months. Xue et al. conducted a meta-analysis study which included clinical trials employing both single and multiple applications of aPDT. They reported that SRP- % aPDT-treated sites had a significant additional benefit in the reduction of probing depth (0.40 mm) but no gain in the clinical attachment level,[25] which is by the current study as there was no additional gain in the CAL after 3 months in Group B [Table 6 and Graph 6b]. Conversely, Leandro Chambrone et al., stated that SRP + aPDT protocol presented with modest additional PPD reduction of 0.43 mm and CAL gain in the treatment of moderate periodontal pockets (5–6 mm).[26] Furthermore, there was a statistically significant reduction in the P. intermedia count from baseline to 6 months in Group A subjects [Table 2 and Graph 2a], whereas recolonization of the pathogens was observed in both the groups, although statistically nonsignificant. In Group A, there was an increase in the P. gingivalis count by 24.7%, and the A. actinomycetemcomitans count was increased by 49.16% at 6 months when compared to baseline [Table 2 and Graph 2a]. Despite the initial reduction, there was recolonization observed which suggests that while tetracycline fibers can reduce the bacterial load temporarily, they do not completely eradicate periodontal pathogens. Recolonization could be due to persistent or dormant bacteria in other parts of the oral cavity (e.g., the tonsils or tongue), which can repopulate the treated sites once the drug delivery is no longer effective. In addition, factors such as the patient’s oral hygiene, bacterial resistance, and the presence of other microorganisms could facilitate recolonization.[27282930] In Group B, A. actinomycetemcomitans count was increased by 118.63% at 6 months compared to baseline [Table 2 and Graph 2b]. While aPDT has been shown to reduce bacterial counts, the ability of a single session of aPDT to completely eradicate all pathogens is limited. Moreover, the increase in A. actinomycetemcomitans could be related to its potential for surviving under low oxygen conditions or its ability to adapt to the local environment after aPDT treatment. In addition, some bacteria may be more resistant to the ROS produced during aPDT or may reestablish from other niches in the oral cavity. In the present investigation, P. gingivalis and A. actinomycetemcomitans were detected before (T0) and after therapy (T6) in a very small number of sites. This persistent pattern observed at baseline and postoperatively may have diagnostic and therapeutic significance. During the first microbiologic examination, organisms were not detected at a larger number of sites. A possible reason could be the presence of target bacteria below the threshold levels on the first visit followed by the multiplication of organisms beyond the minimal concentration for their detection postoperatively (T6).[31] There is an ongoing dispute regarding the advantages and disadvantages of cultural methods compared to the other techniques. Due to contamination or the presence of inhibitors in the sampling material, PCR assays can be falsely positive or falsely negative.[32] There is a high chance for false negative outcomes from a microbiological test when there is a low proportion of positive sites involved. Multiplication of persisting bacteria above threshold levels results in reinfection which is interpreted as reemergence of microorganisms after therapy. The results of the current study are by the research conducted by Mombelli et al. where the authors found that in a few sites, P. gingivalis was seen at 3 months and A. actinomycetemcomitans could be cultivated from one single site. Thus, the authors concluded that there was an effective reduction in the local count of P. gingivalis and A. actinomycetemcomitans with the periodontal therapy using tetracycline fibers, but the target organisms were not completely eradicated.[32] A study conducted by Soeroso et al. reported that repeated subgingival administration of local drug delivery agents led to a significant adjunctive effect for the suppression of recurrence of the disease in combination with SRP.[33] Hence, to prevent microbial recolonization/recurrence of the disease, supportive periodontal care (SPC) by an experienced and skilled dental professional is necessary. Before beginning treatment for periodontitis, patients and dental professionals should understand the likelihood of disease recurrence or progression during SPC, as well as the associated costs and potential harms of retreatments during SPC. CONCLUSION From the observations of the study, the following conclusions were drawn: there was a significant improvement in clinical and microbiological parameters in both the groups at 3 months and 6 months postoperatively suggesting that local drug delivery and PDT can be used as an effective treatment modality as an adjunct to SRP. Microbial recolonization concerning P. gingivalis and A. actinomycetemcomitans was noted in both the groups, albeit without reaching statistical significance at 6 months postoperatively suggesting the importance of supportive periodontal care. The current investigation demonstrated that it is difficult to determine the complete eradication of microorganisms such as P. gingivalis and A. actinomycetemcomitans with a single assessment of a few sites. Limitations of the current study include a short sample size that limits the universality of the findings. Although the current study reports a short follow-up period on clinical and microbiological parameters, a longer follow-up period would help to assess the long-term effectiveness of adjunctive therapies. The microbial analysis focuses only on three microorganisms which are significant pathogens in periodontal disease; however, analysis of a broader spectrum of microbial species could provide a more comprehensive understanding regarding the impact of these adjunctive therapies on the oral microbiome. Furthermore, the microbial recolonization observed could vary based on individual patient factors (e.g. oral hygiene habits), and the study does not control for these factors, which may influence the microbial results. Future directions may include a larger sample size, an extended follow-up period, the inclusion of additional microbial species, the addition of a placebo control group (receiving only SRP), the evaluation of inflammatory biomarkers, and the use of laser-induced fluorescence for a more accurate assessment of microbial load. Conflicts of interest There are no conflicts of interest.